• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长效注射用利培酮(RLAI)是否能减少住院次数?

Does Risperidone Long Acting Injectable Depot (RLAI) Reduce number of Admissions to Hospital.

作者信息

Najim Hellme, Pathak Ashish, Pathak Andrea

机构信息

Essex University Foundation NHS Trust, UK,

出版信息

Psychiatr Danub. 2017 Sep;29(Suppl 3):652-655.

PMID:28953846
Abstract

BACKGROUND

Adherence to treatment is a major issue in relapse prevention in schizophrenia. Injectable depot has been claimed to improve non-adherence. A study in the North of England has shown that risperidone long acting injectable form has reduced number of admissions and number of days stayed in hospital. Our study aimed to replicate the previous study in the South of England.

METHODS

A retrospective study was conducted in the South Essex Foundation University NHS trust. We selected every fifth patient on the Hospital Pharmacy list for risperidone long acting injectable (RLAI). We collected information on. Age, sex, diagnosis and medication ,regular follow up, investigation of each patient which included weight, FBS, S. lipid and hormones at the start of treatment, at three months and six months intervals. We recorded reasons for starting RLAI. Number of antipsychotics prescribed before RLAI, illness duration, number of admissions and days stayed in hospital in each episode before and after RLAI. Patients were included if they stayed for one year or on RLAI.

RESULTS

We reviewed 65 case notes. The most common reason for starting RLAI was non compliance. 80% of our sample had the illness for more than five years. Half of them had physical morbidity. After RLAI was commenced there was a significant association with number and length of admissions.

CONCLUSIONS

We have found an association between prescription of RLAI and reduction in number and length of admission. This needs to be confirmed in a randomised controlled trial.

摘要

背景

坚持治疗是精神分裂症预防复发的一个主要问题。长效注射剂据称可改善治疗依从性。英格兰北部的一项研究表明,利培酮长效注射剂减少了住院次数和住院天数。我们的研究旨在在英格兰南部重复先前的研究。

方法

在南埃塞克斯基础大学国民保健服务信托基金进行了一项回顾性研究。我们从医院药房名单中每隔五位选择一名使用利培酮长效注射剂(RLAI)的患者。我们收集了以下信息:年龄、性别、诊断和用药情况、定期随访情况,对每位患者在治疗开始时、每隔三个月和六个月进行的检查,包括体重、空腹血糖、血脂和激素水平。我们记录了开始使用RLAI的原因。在使用RLAI之前开具的抗精神病药物数量、病程、在使用RLAI之前和之后每次发作的住院次数和住院天数。如果患者使用RLAI达一年或以上,则纳入研究。

结果

我们查阅了65份病例记录。开始使用RLAI的最常见原因是不依从。我们样本中的80%患有该疾病超过五年。其中一半有躯体疾病。开始使用RLAI后,住院次数和住院时间存在显著关联。

结论

我们发现使用RLAI与住院次数和住院时间的减少之间存在关联。这需要在随机对照试验中得到证实。

相似文献

1
Does Risperidone Long Acting Injectable Depot (RLAI) Reduce number of Admissions to Hospital.长效注射用利培酮(RLAI)是否能减少住院次数?
Psychiatr Danub. 2017 Sep;29(Suppl 3):652-655.
2
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.早期精神病的口服与注射用抗精神病药物治疗:两项研究的事后比较
Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.
3
Predictors for starting depot administration of risperidone in chronic users of antipsychotics.抗精神病药物长期使用者开始使用利培酮长效注射剂的预测因素。
J Clin Psychopharmacol. 2008 Dec;28(6):625-30. doi: 10.1097/JCP.0b013e31818a6d10.
4
Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.利培酮长效注射剂对精神科二级护理资源利用的影响。
J Psychopharmacol. 2008 Mar;22(2):128-31. doi: 10.1177/0269881107084068. Epub 2008 Feb 28.
5
A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.长效注射用利培酮与口服非典型抗精神病药物持续治疗首发精神分裂症患者的随机对照试验:初始依从性结果
J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.
6
Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.长效注射利培酮与口服抗精神病药治疗近期发病精神分裂症的疗效比较:一项病例对照研究。
Int Clin Psychopharmacol. 2013 Jul;28(4):164-70. doi: 10.1097/YIC.0b013e3283611cc3.
7
Explicit review of risperidone long-acting injection prescribing practice.利培酮长效注射剂处方实践的明确审查。
J Clin Pharm Ther. 2011 Dec;36(6):651-63. doi: 10.1111/j.1365-2710.2010.01219.x. Epub 2010 Nov 5.
8
Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.长效注射用利培酮用于精神分裂症急性发作后长期治疗的经验:SPHERE研究
Expert Rev Neurother. 2009 Oct;9(10):1463-74. doi: 10.1586/ern.09.96.
9
Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.在加拿大门诊环境中,利培酮长效注射剂与第一代长效抗精神病药物治疗精神分裂症谱系疾病的比较
BMC Psychiatry. 2013 May 30;13:155. doi: 10.1186/1471-244X-13-155.
10
Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.利培酮长效注射剂的早期临床经验:100例患者的前瞻性6个月随访。
J Clin Psychiatry. 2004 Aug;65(8):1076-83. doi: 10.4088/jcp.v65n0808.

引用本文的文献

1
Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta-analysis of observational studies.精神分裂症复发定义对口服与注射用抗精神病药比较疗效的影响:观察性研究的系统评价和荟萃分析。
Pharmacol Res Perspect. 2022 Feb;10(1):e00915. doi: 10.1002/prp2.915.